Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:31 2022-10-06 am EDT
325.55 CHF   -0.75%
08:59aAlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
MT
10/05AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer's disease and Down syndrome
AQ
10/05Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche's Chugai Unit Launches Skin Disease Drug in Japan

08/08/2022 | 03:53am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.13% 3791 Delayed Quote.1.95%
ROCHE HOLDING AG -0.75% 325.55 Delayed Quote.-13.48%
All news about ROCHE HOLDING AG
08:59aAlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
MT
10/05AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Al..
AQ
10/05Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon
AQ
10/05ROCHE HOLDINGS AG : Goldman Sachs gives a Buy rating
MD
10/05Roche to present new data from its expanding neuromuscular disease portfolio at World M..
AQ
10/05Roche Holding AG to Present New Data from Its Expanding Neuromuscular Disease Portfolio..
CI
10/04Global Market Rally Pushes European Stocks Higher; Stoxx 600 Gains More Than 3%
MT
10/04ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
10/04ROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
10/04Switzerland's Roche Secures US FDA Nod for Breast Cancer Drug Enhertu's Companion Diagn..
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 832 M 64 606 M 64 606 M
Net income 2022 14 655 M 14 833 M 14 833 M
Net Debt 2022 11 524 M 11 664 M 11 664 M
P/E ratio 2022 17,5x
Yield 2022 2,96%
Capitalization 268 B 271 B 271 B
EV / Sales 2022 4,38x
EV / Sales 2023 4,22x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 325,55 CHF
Average target price 375,85 CHF
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-13.48%273 724
JOHNSON & JOHNSON-5.35%434 104
ELI LILLY AND COMPANY20.11%315 249
ABBVIE INC.5.86%253 421
PFIZER, INC.-27.03%247 617
NOVO NORDISK A/S7.88%237 650